BR112013015394A2 - método de determinar a presença ou a ausência, em uma amostra biológica de um paciente, de células de câncer de bexiga ou próstata, composto, e, uso de um composto - Google Patents

método de determinar a presença ou a ausência, em uma amostra biológica de um paciente, de células de câncer de bexiga ou próstata, composto, e, uso de um composto

Info

Publication number
BR112013015394A2
BR112013015394A2 BR112013015394A BR112013015394A BR112013015394A2 BR 112013015394 A2 BR112013015394 A2 BR 112013015394A2 BR 112013015394 A BR112013015394 A BR 112013015394A BR 112013015394 A BR112013015394 A BR 112013015394A BR 112013015394 A2 BR112013015394 A2 BR 112013015394A2
Authority
BR
Brazil
Prior art keywords
compound
bladder
patient
absence
determining
Prior art date
Application number
BR112013015394A
Other languages
English (en)
Inventor
Ian Weeks
Mohammed Jaffar
Richard Knox
Original Assignee
Univ Cardiff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cardiff filed Critical Univ Cardiff
Publication of BR112013015394A2 publication Critical patent/BR112013015394A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90209—Oxidoreductases (1.) acting on NADH or NADPH (1.6), e.g. those with a heme protein as acceptor (1.6.2) (general), Cytochrome-b5 reductase (1.6.2.2) or NADPH-cytochrome P450 reductase (1.6.2.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
BR112013015394A 2010-12-20 2011-12-08 método de determinar a presença ou a ausência, em uma amostra biológica de um paciente, de células de câncer de bexiga ou próstata, composto, e, uso de um composto BR112013015394A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1021494.8A GB201021494D0 (en) 2010-12-20 2010-12-20 Compounds
PCT/GB2011/052430 WO2012085532A2 (en) 2010-12-20 2011-12-08 Methods and compounds for detecting cancer

Publications (1)

Publication Number Publication Date
BR112013015394A2 true BR112013015394A2 (pt) 2016-09-20

Family

ID=43598602

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013015394A BR112013015394A2 (pt) 2010-12-20 2011-12-08 método de determinar a presença ou a ausência, em uma amostra biológica de um paciente, de células de câncer de bexiga ou próstata, composto, e, uso de um composto

Country Status (12)

Country Link
US (1) US20140370520A1 (pt)
EP (1) EP2655653B1 (pt)
CN (1) CN103492586A (pt)
AU (1) AU2011346906B2 (pt)
BR (1) BR112013015394A2 (pt)
CA (1) CA2822369A1 (pt)
DK (1) DK2655653T3 (pt)
ES (1) ES2563097T3 (pt)
GB (1) GB201021494D0 (pt)
HK (1) HK1191062A1 (pt)
IN (1) IN2013MN01107A (pt)
WO (1) WO2012085532A2 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2768308T (pt) * 2011-10-14 2018-07-24 Univ Texas Compostos e substratos anti-tumorais nqo1

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070185188A1 (en) * 2006-02-09 2007-08-09 Dorla Mirejovsky Bladder cancer treatment and methods
AU2003261204A1 (en) * 2002-07-23 2004-02-09 Smithkline Beecham Corporation Pyrazolopyrimidines as kinase inhibitors
DE10303265A1 (de) * 2003-01-28 2004-07-29 Roche Diagnostics Gmbh Fluorimetrische Bestimmung von Analyten durch ein intramolekulares Quencher-Fluorophor-Konjugat
WO2009006577A2 (en) * 2007-07-03 2009-01-08 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
TWI354101B (en) * 2008-08-19 2011-12-11 Univ Nat Taipei Technology Fluorimetric indicator for biosensing and manufact
WO2011113018A1 (en) * 2010-03-12 2011-09-15 Ampere Life Sciences, Inc. Measurement and control of biological time

Also Published As

Publication number Publication date
CA2822369A1 (en) 2012-06-28
WO2012085532A2 (en) 2012-06-28
AU2011346906B2 (en) 2016-03-03
US20140370520A1 (en) 2014-12-18
EP2655653A2 (en) 2013-10-30
EP2655653B1 (en) 2015-11-18
DK2655653T3 (da) 2016-02-22
HK1191062A1 (zh) 2014-07-18
AU2011346906A1 (en) 2013-07-04
IN2013MN01107A (pt) 2015-06-12
CN103492586A (zh) 2014-01-01
WO2012085532A3 (en) 2012-08-16
GB201021494D0 (en) 2011-02-02
ES2563097T3 (es) 2016-03-10

Similar Documents

Publication Publication Date Title
IT1406051B1 (it) Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo.
BRPI1007321A2 (pt) métodos para medir e/ou quantificar a presença e/ou quantidade de her-3 ou her-3 em um complexo em uma amostra de um paciente, e para determinar se um indivíduo com um câncer é provável de responder ao tratamento com uma terapia alvejada, e, anticorpo.
WO2009085234A3 (en) Use of micro-rna as a biomarker of immunomodulatory drug activity
BRPI0912292A2 (pt) composições e métodos para o uso de células no tratamento do tecido cardíaco.
EP2642928A4 (en) System for improved tissue handling and in line analysis of the tissue
WO2008073899A3 (en) Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis
ZA201002174B (en) Biological specimen collection and transport system and methods of use
EP2529224A4 (en) Sampling and testing device for the human or animal body
EP2272453A4 (en) THERAPEUTIC SYSTEM, THERAPEUTIC INSTRUMENT AND METHOD FOR ENERGY TREATMENT OF LIVING TISSUES
GB2467467B (en) TAZ/WWTR1 for diagnosis and treatment of cancer
BR112012027574A2 (pt) aparelho e kit de encapsulação de pelo menos um composto para uso terapêutico e/ou em diagnóstico em eritrócitos
BRPI0909954A2 (pt) "diazacarbazóis e métodos de uso"
BRPI0920695A2 (pt) detecção de ácido nucleico npm1 em fluidos corpóreos acelulares
WO2011015602A3 (en) Lung cancer biomarkers
BR112013004458A2 (pt) método e kit para detectar a presença de células que expressam he-4 em um indivíduo humano, e, método para o monitoramento de eficácia de tratamento de um paciente de câncer humano
EP2210101A4 (en) METHODS AND DEVICE FOR DETECTING OCCULT BLOOD
BRPI0813364A2 (pt) Métodos de diagnóstico e tratamento de câncer.
WO2009061800A3 (en) Methods and compositions for diagnostic use in cancer patients
BR112013002441A2 (pt) uso de um anticorpo anti-cd20 afucosilado, composição e método de tratamento de paciente que sofre de câncer
BR112013003530A2 (pt) ''produto farmacêutico, kit, uso e preparações''
EP2278331A4 (en) LEUKOCYTE ANALYSIS METHOD AND ANALYSIS REAGENT FOR USE IN THE PROCESS
BR112013016071A2 (pt) "métodos, dispositivo e kit de diagnóstico de diabete e uso de glioxilato ou um agente de detecção para glioxilato"
WO2012075023A3 (en) Neoantibodies for diagnosing tissue injury
WO2009022988A3 (en) Vhz for diagnosis and treatment of cancer
AU2013231230A8 (en) Method for selecting or identifying a subject for V1B antagonist therapy

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]